# Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients

> **NCT01313273** · PHASE3 · TERMINATED · sponsor: **Ipsen** · enrollment: 3 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Lanreotide, non steroidal anti androgens and LHRH-a
- **DRUG:** Non steroidal anti androgens and LHRH-a

## Key facts

- **NCT ID:** NCT01313273
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Poor enrolment
- **Last updated:** 2019-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01313273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01313273, "Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01313273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*